On June 19, Canopy Growth (WEED) (CGC) and CURE Pharmaceutical announced a partnership to create a new CBD-based oral delivery thin film. The oral thins will be available for distribution globally. Recently, New Age Beverages (NBEV) announced that it will sell its CBD-based products in Hong Kong. To learn more, read NBEV to Sell Its CBD Products in Hong Kong.
Effective dosage control
CURE Pharmaceutical will use its patented technology to develop the new oral thins. The oral thins will help patients administer dosages at precise levels. The patented technology also provides for an increased dosage, which is optimal for the product’s effectiveness. CURE Pharmaceutical’s CEO, Rob Davidson, stated that its “patent secures a critical advantage – the ability to deliver high loads of cannabinoid active molecules with an oral thin film for optimal efficacy and dosing frequency.”
Canopy Growth has continued to expand its product width with several new offerings under its different brands. The company’s strategy is to make cannabis-enabled products that reach a wide variety of customers in different segments and markets.
Previously, Canopy Growth indicated that it’s pursuing a market for cannabis that’s more value-added and product-based for the recreational market. The value addition will include edibles, beverages, and higher concentrated vaping oils. On the medical side, the oral thins open up new doors for Canopy Growth to capture revenue growth from medical patients.